💎 Fed’s first rate cut since 2020 set to trigger market. Find undervalued gems with Fair ValueSee Undervalued Stocks

Humana eyes stronger ties with Walmart despite Walgreens partnership

Published 08/01/2018, 11:40 AM
Updated 08/01/2018, 11:50 AM
© Reuters.  Humana eyes stronger ties with Walmart despite Walgreens partnership
WMT
-
HUM
-
WBA
-
UNH
-

By Tamara Mathias and Ankur Banerjee

(Reuters) - Humana Inc (N:HUM) said it was looking to expand its tie-up with Walmart (N:WMT), easing concerns that the insurer's agreement with drugstore chain Walgreens Boots Alliance (O:WBA) would prevent it from broadening its partnership with the retailer.

Humana's shares rose about 4 percent to a record high of $326.97 after Chief Executive Bruce Broussard's comments on a call discussing the company's better-than-expected earnings.

"We still value and have a strong relationship with Walmart," Broussard said, adding that the insurer is looking at ways to expand the partnership.

Walmart currently has a co-branded Medicare drug plan with Humana that steers patients to Walmart stores. The partnership offers a prescription drug plan that can save up to 20 percent in drug costs for customers.

In June, the insurer announced it would partner with Walgreens, with its unit operating senior-focused primary care clinics inside two Walgreens stores in Kansas, a move some analysts said at the time ended any speculation over a deal with Walmart.

Reuters reported in March that Walmart was in early talks with Humana about developing closer ties, with a possible acquisition on the table.

"Both of them (ties to Walmart and Walgreens) are complementary," Broussard said, adding partnering with one does not restrict the other deal.

Unlike its rivals, Humana has said it will focus on partnerships and smaller deals while cementing its dominance in the Medicare Advantage business, which powered a better-than- expected second quarter profit.

Humana, in the past few months, has joined hands with private equity firms to buy health care services companies, creating the largest hospice operator in the United States.

RAISES FORECAST

Humana also raised its 2018 adjusted earnings forecast to about $14.15 per share from its previous forecast of $13.70 to $14.10 per share.

The company's adjusted consolidated benefit ratio, the percentage of premiums spent on claims, deteriorated to 84.3 percent in the quarter, missing consensus estimate of 83.9 percent according to brokerage Evercore ISI.

Over the past few quarters, insurers have kept a tight leash on medical costs and even a slight slip has weighed on stocks.

Earlier this month, the largest U.S. health insurer UnitedHealth Group (N:UNH) reported quarterly medical costs slightly higher than expected, overshadowing a second quarter profit beat.

Excluding items, Humana earned $3.96 per share, beating analysts' average estimate of $3.77, according to Thomson Reuters I/B/E/S.

Revenue rose 5.4 percent to $14.26 billion, above the average estimate of $14.16 billion.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.